![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Interleukin-6 (IL-6) receptor blockers improve systemic inflammation, however, their inconsistent effects on lipid metabolism and drug-induced liver injuries warrant further investigation. This study aimed to determine the effects of IL-6 receptor blocker therapy on lipid metabolism and liver morphology in collagen-induced arthritis.
Methods: Sixty three Sprague Dawley rats were divided into control (n = 24), inflammation (n = 24), and IL-6 blocker (n = 15) groups. Inflammation was induced in the inflammation and IL-6- blocker groups using Bovine type-II collagen and incomplete Freund’s adjuvant. At first signs of arthritis, the IL-6 blocker group received an IL-6 blocker, tocilizumab for six weeks. Serum concentrations of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and ATP-binding cassette transporter-A1 (ABCA1) were measured. Liver fibrosis was determined by histological stains and liver enzymes were measured using the colorimetric-chemistry analyzer.
Results: In the inflammation group, HDL-C and ABCA1 were reduced compared to control (p < 0.0001 and p = 0.04, respectively) and IL-6 blocker (p = 0.0003 and p < 0.0001, respectively) groups. LDL-C was increased in the inflammation compared to control (p = 0.02). Markers of liver fibrosis were increased in the IL-6 blocker group compared to control and inflammation groups (picrosirius red collagen area fraction: p < 0.0001 and p = 0.0008, respectively; Masson’s trichrome collagen area fraction: p = 0.0002 and p = 0.01, respectively). Alkaline phosphatase concentrations were increased in the IL-6 blocker group compared to the control (p < 0.0001) and inflammation (p = 0.002) groups.
Conclusion: IL-6 blockers ameliorated inflammation-induced lipid metabolism impairments, however they induced liver fibrosis. Although IL-6 blockers may reduce inflammation-induced metabolic impairments in chronic inflammatory disorders, routine monitoring of liver function is warranted while on treatment.
Keywords: Inflammation, lipid metabolism, liver fibrosis, IL-6 receptor blocker, collagen-induced arthritis, tocilizumab.
[PMID: 31504942]
[http://dx.doi.org/10.1136/annrheumdis-2011-200726] [PMID: 22425941]
[http://dx.doi.org/10.1038/s41584-020-0428-y] [PMID: 32494054]
[http://dx.doi.org/10.1016/j.jjcc.2018.05.010] [PMID: 29907363]
[http://dx.doi.org/10.3390/ijms21249505] [PMID: 33327502]
[http://dx.doi.org/10.1038/nrrheum.2013.91] [PMID: 23774906]
[http://dx.doi.org/10.1007/s00296-020-04616-2] [PMID: 32524301]
[http://dx.doi.org/10.1136/annrheumdis-2013-204715] [PMID: 24796336]
[http://dx.doi.org/10.1016/j.semarthrit.2020.11.005] [PMID: 33385862]
[http://dx.doi.org/10.1080/14397595.2018.1546357] [PMID: 30427250]
[http://dx.doi.org/10.1097/RHU.0000000000001293] [PMID: 31876844]
[http://dx.doi.org/10.3390/ijms20184633]
[http://dx.doi.org/10.1002/jcsm.12189] [PMID: 28316139]
[http://dx.doi.org/10.1097/RHU.0000000000001657] [PMID: 33394831]
[http://dx.doi.org/10.1155/2018/2453265] [PMID: 30405318]
[http://dx.doi.org/10.1371/journal.pone.0130709] [PMID: 26114946]
[http://dx.doi.org/10.1136/annrheumdis-2013-204345] [PMID: 24368514]
[PMID: 27069354]
[http://dx.doi.org/10.1002/art.40176] [PMID: 28597609]
[http://dx.doi.org/10.3899/jrheum.130924] [PMID: 24786929]
[PMID: 23819335]
[http://dx.doi.org/10.1111/j.1872-034X.2011.00793.x] [PMID: 21435128]
[http://dx.doi.org/10.1111/liv.14516] [PMID: 32478465]
[PMID: 33427610]
[http://dx.doi.org/10.1016/j.ejphar.2019.172786] [PMID: 31712060]
[http://dx.doi.org/10.2174/1871530320999200818103709] [PMID: 32811421]
[http://dx.doi.org/10.1007/s00428-012-1271-6] [PMID: 22772768]
[http://dx.doi.org/10.1016/j.metabol.2015.11.008] [PMID: 26775559]
[PMID: 30568700]
[http://dx.doi.org/10.1007/s40744-016-0049-8] [PMID: 27900570]
[http://dx.doi.org/10.1016/j.bbadis.2018.12.019] [PMID: 30593897]
[http://dx.doi.org/10.1186/s13075-020-02307-8] [PMID: 32917272]
[http://dx.doi.org/10.1371/journal.pone.0164564] [PMID: 27736980]
[http://dx.doi.org/10.1186/s13075-015-0559-8] [PMID: 25889426]
[http://dx.doi.org/10.21203/rs.3.rs-61508/v1]
[http://dx.doi.org/10.1016/j.cell.2017.05.020] [PMID: 28602350]
[http://dx.doi.org/10.1038/s41467-022-32437-3] [PMID: 35974019]
[http://dx.doi.org/10.1016/j.bbalip.2012.08.011] [PMID: 22940078]
[http://dx.doi.org/10.1530/JME-18-0167] [PMID: 30131353]
[http://dx.doi.org/10.1074/jbc.M111.264325] [PMID: 21757719]
[http://dx.doi.org/10.1371/journal.pone.0109722] [PMID: 25329888]
[http://dx.doi.org/10.1016/j.dsx.2019.03.004] [PMID: 31336517]
[http://dx.doi.org/10.1038/nrrheum.2010.105] [PMID: 20647995]
[http://dx.doi.org/10.1042/bse0420089] [PMID: 17144882]
[http://dx.doi.org/10.1038/s42255-021-00470-z] [PMID: 34650277]
[http://dx.doi.org/10.1136/annrheumdis-2017-211708] [PMID: 28916714]
[http://dx.doi.org/10.3390/antiox10010045] [PMID: 33401700]
[http://dx.doi.org/10.1136/bmjgast-2019-000349] [PMID: 32377366]
[http://dx.doi.org/10.2147/TCRM.S172836] [PMID: 30349273]
[http://dx.doi.org/10.1016/j.jhep.2016.02.004] [PMID: 26867490]
[http://dx.doi.org/10.1097/MEG.0000000000001336] [PMID: 30543572]
[http://dx.doi.org/10.2147/CPAA.S24004] [PMID: 22287855]
[http://dx.doi.org/10.3748/wjg.v22.i48.10512]
[http://dx.doi.org/10.1016/j.taap.2018.07.014] [PMID: 30025850]
[http://dx.doi.org/10.1155/2013/964828] [PMID: 25374723]
[http://dx.doi.org/10.1177/1756284820959183] [PMID: 33101458]
![Wayfinder Image](/images/wayfinder.jpg)